16 results about "Right ventricular hypertrophy" patented technology

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition and application thereof in preparation of a medicine for treating the heart-lung qi deficiency type pulmonary heart disease. The pharmaceutical composition consists of 21-27 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 7-10 parts of cassia twig, 21-27 parts of ligusticum wallichii, 7-10 parts of rhizoma alismatis, 5-7 parts of platycodon grandiflorum and 2-4 parts of Chinese dates. Compared with the prior art, the cassia twig is adopted to replace fructus psoraleae in an original formula, and meanwhile, the medicinal material specifications of the fried semen descurainiae, the raw ligusticum wallichii and the salted rhizoma alismatis are preferably selected. The invention also provides three preparation methods of the pharmaceutical composition, namely a water extraction and alcohol precipitation method, an alcohol extraction and water extraction combined method and a crushing and mixing method. Experimental results show that the pharmaceutical composition has remarkable effects on improving heart functions, lung functions, blood-gas indexes, right ventricular hypertrophy and the like of pulmonary heart disease model animals, meanwhile, the hepatotoxicity risk of fructus psoraleae is avoided, and the pharmaceutical composition has a good clinical application prospect.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and / or treating the PH. Since a protein level and / or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement / right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

The invention provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and application thereof, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition for treating pulmonary arterial hypertension is prepared from the following components in parts by weight: 5-7 parts of herba ephedrae, 7-9 parts of semen armeniacae amarae, 20-24 parts of gypsum, 5-7 parts of liquorice root, 9-11 parts of radix salviae miltiorrhizae, 0.8-1.2 parts of leech and 2.5-3.5 parts of radix notoginseng. According to the treatment principle of freeing lung, relieving asthma and promoting blood circulation to remove blood stasis, ephedra, apricot kernel, gypsum and licorice granules with the effects of freeing lung, clearing heat and relieving asthma are used as monarch drugs, and salvia miltiorrhiza, leech and pseudo-ginseng with the effects of promoting blood circulation to remove blood stasis are used as ministerial drugs for compatibility; the prepared traditional Chinese medicine composition can reduce the length ratio of the right ventricle to the left ventricle plus ventricular septum and the length ratio of the right ventricle to the tibia, inhibit right ventricular hypertrophy, repair pulmonary vascular injury and improve the pulmonary ventilation function, the cardio-pulmonary function and pulmonary arterial hypertension.

Methods of treating, preventing, or reducing the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing, or reducing the progression rate and / or severity of one or more PH-related complications, are provided.SOLUTION: In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of PH. The disclosure also provides methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The present disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.SELECTED DRAWING: None

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

A use of a trisaccharide compound having a core structure of GlcN(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing pulmonary hypertension. The drug can effectively alleviate right ventricular hypertrophy and right ventricular dysfunction and optimize hemodynamic parameters in an animal model of pulmonary hypertension, slow down or ameliorate excessive proliferation of arterial endothelial cells and smooth muscle cells in pulmonary hypertension, treat vascular remodeling and vascular muscularization in patients with pulmonary hypertension, and has a good protective effect on a heart in pulmonary hypertension.

The application provides a traditional Chinese medicine composition for treating pulmonary arterial hypertension and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is composed of ginseng, astragalus, cassia bark, prepared licorice, prepared rehmannia, angelica, white peony root, chuanxiong, persicae semen and safflower. The preparation method is as follows: water is added to decoct and extract to obtain a traditional Chinese medicine extract; the traditional Chinese medicine extract can be further concentrated into a clear paste, and excipients are added to prepare other dosage forms. Animal experiments show that the traditional Chinese medicine composition can significantly reduce the pulmonary arterial pressure of a hypoxic pulmonary arterial hypertension model rat, reduce the right ventricular hypertrophy index, reduce the wall thickness percentage and area percentage of pulmonary arterioles, increase the lumen area percentage of pulmonary arterioles, and effectively improve pulmonary vascular remodeling; clinical cases show that the traditional Chinese medicine composition can significantly improve the symptoms of pulmonary arterial hypertension and heart failure. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, removing blood stasis and dredging collaterals, can be used for preventing and / or treating pulmonary arterial hypertension, and has good safety.

The invention provides application of ginsenoside F5. The ginsenoside F5 is used for reducing right ventricular systolic pressure, reducing right ventricular hypertrophy index, reversing vascular remodeling of pulmonary arterial hypertension and relieving pulmonary arterial vascular injury, and is used for preparing medicines for preventing and / or improving pulmonary arterial hypertension. The ginsenoside F5 can effectively improve pulmonary vascular remodeling of animals with pulmonary arterial hypertension, reduce right ventricular systolic pressure, relieve right ventricular hypertrophy, increase the survival rate of the animals with pulmonary arterial hypertension and relieve pulmonary artery vascular injury. The ginsenoside F5 has a certain improvement effect on the pulmonary arterial hypertension, is expected to become a new drug target for treating the pulmonary arterial hypertension, can be used as a drug for preventing and treating the pulmonary arterial hypertension, and is used for preventing and improving the pulmonary arterial hypertension.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition and application thereof in preparation of a medicine for treating chronic pulmonary heart disease. The pharmaceutical composition consists of 21-27 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 7-10 parts of cassia twig, 21-27 parts of ligusticum wallichii, 7-10 parts of rhizoma alismatis, 5-7 parts of platycodon grandiflorum and 2-4 parts of Chinese dates. Compared with the prior art, the cassia twig is adopted to replace fructus psoraleae in an original formula, and meanwhile, the medicinal material specifications of the fried semen descurainiae, the raw ligusticum wallichii and the salted rhizoma alismatis are preferably selected. The invention also provides three preparation methods of the pharmaceutical composition, namely a water extraction and alcohol precipitation method, an alcohol extraction and water extraction combined method and a crushing and mixing method. Experimental results show that the pharmaceutical composition has remarkable effects on improving heart functions, lung functions, blood-gas indexes, right ventricular hypertrophy and the like of pulmonary heart disease model animals, meanwhile, the hepatotoxicity risk of fructus psoraleae is avoided, and the pharmaceutical composition has a good clinical application prospect.

This invention discloses a recombinant gene expression vector and its use in the preparation of drugs for treating pulmonary arterial hypertension (PAH). The vector contains a nucleotide sequence encoding a small activating RNA (saRNA), which specifically targets and upregulates the expression of the endogenous Ste20-like kinase gene. Based on the discovery that SLK gene expression is significantly downregulated in vascular smooth muscle cells of PAH, this invention utilizes an RNA activation mechanism to activate the transcription and expression of the endogenous SLK gene by delivering specific saRNA to the lesion site. The vector can employ a vascular smooth muscle cell-specific promoter and an optimized miRNA backbone to achieve tissue-specific and highly efficient expression. The recombinant vector of this invention effectively inhibits the excessive proliferation and migration of pulmonary artery smooth muscle cells, alleviates right ventricular hypertrophy, reverses pulmonary vascular remodeling, and significantly reduces pulmonary artery pressure, providing a novel target and gene therapy strategy for the clinical treatment of PAH.

There was a need for safe and effective treatments for pulmonary hypertension, especially pulmonary arterial hypertension (PAH). The inventors discovered dysregulation of the kynurenine pathway (KP) in the lungs of PAH patients, marked by an imbalance of KP metabolites and upregulation of key enzymes, particularly kynurenine 3-monooxygenase (KMO). This disclosure pertains to a kynurenine-3-monooxygenase inhibitor for use in the treatment or prevention of pulmonary hypertension, in particular pulmonary arterial hypertension. The kynurenine-3- monooxygenase inhibitor is effective in reducing vascular and cardiac remodeling, decreasing right ventricular systolic pressure, reducing pulmonary ventricular resistance, decreasing medial hypertrophy of large arteries, lowering the proportion of muscularized and occluded small arteries and decreasing right ventricular hypertrophy.

The application belongs to the technical field of medicine, and particularly relates to application of namodenoson in prevention and treatment of pulmonary arterial hypertension. The application discloses that, as a specific small molecule inhibitor, namodenoson can effectively block the physical interaction between SHMT2 and RhoB, restore the ubiquitination degradation of RhoB, and thus reverse the rearrangement of endothelial cell skeleton and the damage of barrier function caused by overexpression of SHMT2. In a pulmonary arterial hypertension animal model, treatment with namodenoson can significantly reduce the mean pulmonary arterial pressure and the right ventricular systolic pressure, reduce the right ventricular hypertrophy, and improve the pulmonary vascular remodeling. The above protective effect of namodenoson is achieved by specific intervention on the SHMT2-RhoB axis, and the use of namodenoson in the treatment of PH can greatly shorten the period of preclinical and clinical research, reduce the research and development risk, and has extremely high clinical conversion value and market prospect.